178 related articles for article (PubMed ID: 8750529)
21. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
22. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
23. int-2 and c-erbB-2 gene amplification detected in 70 frozen human breast carcinomas by quantitative polymerase chain reaction.
An HX; Niederacher D; Dominik SI; Kuschel B; Yan H; Dall P; Schnürch HG; Bender HG; Beckmann MW
Anticancer Res; 1997; 17(4B):3133-6. PubMed ID: 9329619
[TBL] [Abstract][Full Text] [Related]
24. Gene amplification of int-2 and erbB in human esophageal cancer: relationship to clinicopathological variables.
Suzuki H; Abo S; Kitamura M; Hashimoto M; Izumi K; Terada K; Sugiyama T
Cancer Invest; 1997; 15(5):411-5. PubMed ID: 9316622
[TBL] [Abstract][Full Text] [Related]
25. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases.
Tsuda H; Sakamaki C; Tsugane S; Fukutomi T; Hirohashi S
Breast Cancer Res Treat; 1998 Mar; 48(1):21-32. PubMed ID: 9541186
[TBL] [Abstract][Full Text] [Related]
26. Oncogene amplifications in early-stage human prostate carcinomas.
Latil A; Baron JC; Cussenot O; Fournier G; Boccon-Gibod L; Le Duc A; Lidereau R
Int J Cancer; 1994 Dec; 59(5):637-8. PubMed ID: 7960236
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of accumulation of gene and chromosome alterations and histological grade in node-negative breast carcinoma.
Tsuda H; Sakamaki C; Tsugane S; Fukutomi T; Hirohashi S
Jpn J Clin Oncol; 1998 Jan; 28(1):5-11. PubMed ID: 9491134
[TBL] [Abstract][Full Text] [Related]
28. [Abnormalities and clinical characteristics of growth factors and receptor systems in breast cancer].
Kikuchi K; Ueda M; Ikeda T; Enomoto K; Kitajima M
Gan To Kagaku Ryoho; 1994 Jun; 21 Suppl 2():168-71. PubMed ID: 7913599
[TBL] [Abstract][Full Text] [Related]
29. Classical gene amplifications in human breast cancer are not associated with distant solid metastases.
Driouch K; Champème MH; Beuzelin M; Bièche I; Lidereau R
Br J Cancer; 1997; 76(6):784-7. PubMed ID: 9310246
[TBL] [Abstract][Full Text] [Related]
30. Oncogene amplification per se: an independent prognostic factor in human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mol Carcinog; 1994 Dec; 11(4):189-91. PubMed ID: 7999260
[TBL] [Abstract][Full Text] [Related]
31. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
32. Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.
Olsson H; Borg A; Fernö M; Ranstam J; Sigurdsson H
J Natl Cancer Inst; 1991 Oct; 83(20):1483-7. PubMed ID: 1920494
[TBL] [Abstract][Full Text] [Related]
33. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis.
Fajac A; Benard J; Lhomme C; Rey A; Duvillard P; Rochard F; Bernaudin JF; Riou G
Int J Cancer; 1995 Apr; 64(2):146-51. PubMed ID: 7615357
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
35. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol.
Hartmann LC; Ingle JN; Wold LE; Farr GH; Grill JP; Su JQ; Maihle NJ; Krook JE; Witzig TE; Roche PC
Cancer; 1994 Dec; 74(11):2956-63. PubMed ID: 7954259
[TBL] [Abstract][Full Text] [Related]
37. A paradigm for oncogene complementation in human breast cancer.
Roux-Dosseto M; Martin PM
Res Virol; 1989; 140(6):571-91. PubMed ID: 2694252
[TBL] [Abstract][Full Text] [Related]
38. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
Lassus H; Leminen A; Vayrynen A; Cheng G; Gustafsson JA; Isola J; Butzow R
Gynecol Oncol; 2004 Jan; 92(1):31-9. PubMed ID: 14751135
[TBL] [Abstract][Full Text] [Related]
39. C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis.
Parkes HC; Lillycrop K; Howell A; Craig RK
Br J Cancer; 1990 Jan; 61(1):39-45. PubMed ID: 2153396
[TBL] [Abstract][Full Text] [Related]
40. Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates.
Forus A; Høifødt HK; Overli GE; Myklebost O; Fodstad O
Mol Pathol; 1999 Apr; 52(2):68-74. PubMed ID: 10474684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
